Helixmith Recommends Park Young-joo as Internal Director and Head of Clinical Development Division

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 11th that it recommends Park Youngjoo, Head of Clinical Development Division/Head of U.S. Corporation, as a new internal director candidate. At the board meeting held on the 10th, the agenda items to be submitted to the 26th regular general shareholders' meeting to be held on the 31st were finalized, including the appointment of a new internal director.

Park Youngjoo, Head of Clinical Development Division, earned a master's and doctoral degree in statistical epidemiology from Seoul National University Graduate School of Public Health and has continuously worked in the pharmaceutical and bio industries, building experience in the field of clinical trials. Park has proven her capabilities by overseeing clinical trials not only in the U.S. but also in Korea and India.

In particular, she has established a separate financial accounting function within the clinical division to further enhance the efficiency, expertise, and transparency of expenses. U.S. clinical trials have very complex operations, standards, and classification systems, making it difficult even for experts without global clinical experience to understand the details.

Helixmith CEO Yoo Seungshin said, “Park has been involved in clinical development at global pharmaceutical companies and venture firms for over 20 years, and she possesses excellent insight into planning, executing, and managing related budgets, so I believe she will play a very significant role as an internal director.” He explained the recommendation background, saying, “If Dr. Park Youngjoo becomes an internal director, Helixmith will have two female executives, establishing a management system that leads the bio industry in line with global ESG trends.”

Since 1996, Park has gained diverse experience across all areas of clinical development, including clinical trial planning, data management, biostatistics, safety management, MW (Medical Writing), and global clinical management at global pharmaceutical companies MSD and Sanofi for over 20 years. She also served as the head of the global R&D organization in Korea for about 10 years, gaining extensive experience in personnel, budget planning and execution, and organizational management. Since joining Helixmith in 2020, she has demonstrated outstanding skills in organizational operation and financial management while leading the clinical division, especially U.S. clinical trials, alongside CEO Kim Sunyoung.

The Helixmith internal board of directors previously consisted of five members, including CEO Kim Sunyoung, CEO Yoo Seungshin, and Director Seo Jehee, but with Director Seo’s term expiring at this shareholders' meeting, there is an opportunity to appoint one internal director. The outside board of directors, composed of three members including Professor Chas Bountra of Oxford University and former Fair Trade Commission Chairman Noh Daerae, remains unchanged.

This content was produced with the assistance of AI translation services.